Rationale: Primary central nervous system histiocytic sarcoma (PCNSHS) is a rare lymphohematopoietic tumor with a histiocytic cell origin. To our knowledge, only 28 cases have been published in English and 2 cases in Chinese.
Introduction
Histiocytic sarcomas (HS) are rare malignant lymphohematopoietic tumors with morphologic and immunophenotypic features of mature tissue histiocytes. This diagnosis accounts for < 1% of non-Hodgkin's lymphoma, [1] and most frequently arises in lymph nodes, skin, and the intestinal tract. Primary central nervous system histiocytic sarcoma (PCNSHS) is extremely rare. To our knowledge, only 30 total cases have been published in English and Chinese literature. We report a case of a 49-year-old Asian female with PCNSHS, as well as a thorough discussion of the differential diagnosis of PCNSHS and a review of the clinical and pathological features of previously published cases.
Case presentation
A 49-year-old Asian female presented to the hospital with a 2 month history of hypomnesia, odynophagia, and gait disorder.
She denied a history of fever, pruritis, and a personal or family history of malignancy. Physical examination revealed stable vital signs, decreased memory, and a decreased lower extremity muscle strength of 3/5. Laboratory findings demonstrated normal a complete blood count, renal function, liver function tests, thyrotropin, and erythrocyte sedimentation. Serum tumor markers including carcinoembryonic antigen (CEA) and afetoprotein (AFP) were within normal limits. Computerized tomography (CT) scan and magnetic resonance imaging (MRI) of the brain demonstrated a 2.5 cm, well-circumscribed, uniformly enhancing lesion in the parietal lobe. Staging bone marrow and positron emission tomography/CT showed no evidence of disease outside of the central nervous system (CNS). A gross total resection of the tumor by imaging criteria was performed. On gross examination, the tumor was 2.5 Â 2.2 Â 2 cm with a soft texture and gray to red color. Microscopic examination revealed marked disruption of the normal brain architecture by numerous (Fig. 1A) . At high magnification, the tumor cells were highly pleomorphic and exhibited eosinophilic cytoplasm. The nuclei were medium to large in size with a distinct oval to kidney shape, thickened nuclear membranes and granular chromatin. Prominent single nucleoli and multiple small nucleoli were observed (Fig. 1B) . The background consisted of inflammatory cells, hemorrhage and congested vessels. Polynuclear tumor cells were occasionally identified ( Fig. 1C and D) . Calcification was present, but was not a predominant feature (Fig. 1E ). Vascular invasion was easily identified (Fig. 1F) . The tumor cells demonstrated strong cytoplasmic immunoreactivity for lysozyme, CD68, and CD163 ( Fig. 2A and B), focal cytoplasmic and nuclear immunoreactivity for S100, membrane immunoreactivity for CD45 (Fig. 2C) , and the Ki-67 proliferation index was approximately 60% (Fig. 2D ). The tumor cells were negative for pan-CK, EMA, GFAP, CD3, CD20, CD1a, CD79a, CD138, olig2, and CD15, melan-A, CD30, CD21, CD35, HMB45, ALK-1. Both morphology and immunophemotype confirm the diagnosis of PCNSHS. The patient received 45 Gray of adjuvant external beam radiation to the tumor bed with generous margins. Unfortunately, she died 8 months after her initial diagnosis.
Discussion
PCNSHS is a rare and difficult diagnosis due to the heterogeneous and somewhat nonspecific histopathologic appearance. According to the World Health Organization (WHO), the diagnosis of HS requires verification of the histiocytic lineage and exclusion of other lymphohematopoetic malignancies. [2] Histologically, PCNSHS demonstrates large, pleomorphic cells, with abundant eosinophilic cytoplasm, irregular nuclei with prominent nucleoli, mitotic figures, and necrosis. PCNSHS may have tumor giant cells, erythrophagocytosis, or focal spindling. [3] [4] [5] [6] [7] [8] Prominent acute and chronic inflammation was found in approximately 60% cases, [3] and could be a useful clue for the diagnosis. The morphology of the present case meets the criteria and histopathologic findings of previously published cases of PCNSHS.
Immunohistochemistry plays an important role in the diagnosis of PCNSHS, and a comprehensive workup is warranted, including pan-CK and EMA to rule out carcinoma and meningioma; GFAP and olig2 for glial-derived tumors (especially pleomorphic xanthoastrocytoma); and S100 for melanoma, interdigitating dendritic cell sarcoma, and Rosai-Dorfman disease. However, S100 is positive in approximately 33% of HS, therefore, a positive S100 does not rule out HS,. [9] In our case, pan-CK, EMA, GFAP, olig2 were negative but CD45 was positive, suggesting a lymphohematopoietic cell lineage.
CNS lymphoma constitutes a rare group of tumors. The majority of these non-Hodgkin's lymphomas (NHL) are derived from B lymphocytes. [10] Considering the positive CD45 immunohistochemistry and morphologic findings, the main differential diagnosis was diffuse large B cell lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL). Following immunohistochemistry showed negative immunoreactivity for CD20, CD79a, PAX5, CD3, CD15, CD30 and ALK-1, effectively excluding B and T cell lymphomas. CD1a was negative, excluding Langerhans cell neoplasms; CD21, CD35, and CD23 were negative excluding follicular dendritic cell sarcoma; CD138 negativity excluded plasma cell neoplasms; negativity for MPO, CD117, and CD34 excluded myeloid sarcoma. The tumor cells stained positive for CD68, lysozyme, and CD163 suggesting a histiocytic origin. The Ki-67 proliferation index of reported cases ranges from 10% to 90%. The Ki-67 proliferation index of our case was 60%, indicating a high grade malignancy. [11] PCNSHS has a very aggressive clinical course with a poor prognosis. The median survival is 7 ± 0.98 months (95%CI: 5.08-8.92) and the average survival is 24.07 ± 5.1 months (95% CI: 14.08-34.06) (Table 1, Fig. 3) . [1] [2] [3] [4] [5] [6] [7] [8] [9] Brown et al reported the longest survival at greater than 60 months. The most common treatment reported was a combination of surgery, radiotherapy and chemotherapy (Table 1) . Currently, no standardized treatment protocol exists. For patients with a single tumor, surgery is the preferred treatment strategy. Due to the limited number of the cases, we are unable to reach a conclusion regarding if chemotherapy or radiotherapy can effectively control the disease. Chemotherapy regimens including ICE (cyclophosphamide, carboplatin, and etoposide) and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) did not show obvious prognostic improvement. No clear dose radiotherapy has been established.
Conclusion
In conclusion, we present a case of PCNSHS, including the histopathologic and immunohistochemical findings, and the aggressive clinical course. We reviewed all previous publications and conclude that PCNSHS is a rare, aggressive malignancy which most frequently involves brain parenchymal. Due to the rarity and large differential diagnosis, a full immunohistochemical work up is warranted. More research is required to determine the best treatment options. We encourage physicians to publish cases of PCNSHS in order to compile additional data that will assist in developing optimal treatment regimens.
